AMPLATZER versus Figulla occluder for transcatheter patent foramen ovale closure

EuroIntervention 2017;12:2092-2099. DOI: 10.4244/EIJ-D-15-00499

Daniela Trabattoni
Daniela Trabattoni1, MD, FESC; Achille Gaspardone2*, MD, MPhil, FESC; Gregory A. Sgueglia2, MD, PhD; Franco Fabbiocchi1, MD; Gaetano Gioffrè2, MD; Piero Montorsi1, MD; Giuseppe Calligaris1, MD; Maria Iamele2, MD; Antonella De Santis2, MD; Antonio L. Bartorelli1, MD, FESC
1. Centro Cardiologico “Monzino” IRCCS and Department of Cardiovascular Sciences, University of Milan, Milan, Italy; 2. U.O.C. di Cardiologia, Ospedale Sant’Eugenio, Rome, Italy

Aims: The aim of this observational study was to compare acute and 12-month results of percutaneous closure of patent foramen ovale (PFO) with two occluder devices.

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

closure devicespatent foramen ovalepercutaneous closure
Interventions for strokeOther stroke interventions(includes ASD / PFO closure)
Read next article
Are the AMPLATZER Duct Occluder II Additional Sizes devices dedicated only for smaller children?

Latest news